Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Inovio Pharmaceuticals news
11.05.2022
Inovio Pharmaceuticals' GAAP loss for 3 months of 2022 was $79.909 million, up 48.1% from $53.968 million in the previous year. Revenue decreased 46.4% to $199,074 thousand compared to $371,12 thousand a year earlier.
Source: 
ir.inovio.com
ir.inovio.com
02.03.2022
Inovio Pharmaceuticals' GAAP loss for 2021 was $303.659 million, up 81.3% from $167.475 million in the previous year. Revenue decreased 76% to $1,775 million from $7,411 million a year earlier.
Source: ir.inovio.com
ir.inovio.com
10.11.2021
Inovio Pharmaceuticals' GAAP loss for 9M 2021 was $196.711 million, up 37.4% from $143.137 million in the previous year. Revenue decreased 48.9% to $0.936 million from $1.831 million a year earlier.
Source: ir.inovio.com
ir.inovio.com
09.08.2021
Inovio Pharmaceuticals' GAAP loss for 6M 2021 was $136.542 million, down 15.9% from $162.308 million in the previous year. Revenue decreased 2.5 times to $0.644 million from $1.595 million a year earlier.
Source: ir.inovio.com
ir.inovio.com
General information
| Company name | Inovio Pharmaceuticals |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 660 West Germantown Pike Suite 110 Plymouth Meeting, PA 19462 United States |
| Mailing address | 660 West Germantown Pike Suite 110 Plymouth Meeting, PA 19462 United States |
| Website | ir.inovio.com |
| Information disclosure | www.sec.gov |
English (US) 